Patent ID: 6514979
Filing Date: 2003-02-04
Classification: A61K

Abstract:
A pharmaceutical composition comprising:a) at least one guanosine analog reverse transcriptase inhibitor selected from the group consisting of: (âˆ’)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol, a racemic of (âˆ’)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol with the (+)-cis enantiomer thereof, (âˆ’)-cis-4-[2-amino-6-(cyclopropylmethylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol, and a racemic mixture of (âˆ’)-cis-4-[2-amino-6-(cyclopropylmethylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol with the (+)-cis enantiomer thereof; and b) at least one inosine monophosphate dehydrogenase inhibitor, wherein the inosine monophosphate dehydrogenase inhibitor is a mycophenolate, and wherein the amount of the inosine monophosphate dehydrogenase inhibitor is less than the amount of the guanosine analog reverse transcriptase inhibitor and the combination provides a synergistic effect in the treatment of viral infections.